Gilead Sciences Inc (GILD)

[Tha Part Time Er]

Gilead Sciences, Inc. GILD primarily focuses on developing drugs for the treatment of HIV, liver, hematology/oncology and inflammation/respiratory diseases. It is looking to diversify its business as the HCV business has lost sheen. The HIV business maintains momentum for the company, driven by Biktarvy. The company is also bolstering the oncology pipeline with collaborations. Importantly, the company has been in the news from the onset of the year owing to its promising experimental coronavirus treatment, remdesivir. It recently reported mixed results from a late-stage study on investigational antiviral, remdesivir, in hospitalized patients with moderate COVID-19 pneumonia. The FDA has also granted remdesivir an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19, given the severity of the pandemic. The drug is currently approved in Japan as a treatment for patients infected with COVID-19. A potential approval of remdesivir will be a significant boost for the company.

Gilead currently carries a Zacks Rank #2 (Buy).